#Halozyme #ENHANZE #Drug Delivery

Halozyme Therapeutics Forecasts Minimal Impact on Royalty Revenue

Halozyme Therapeutics, Inc., a pioneering biopharmaceutical company based in San Diego, has publicly addressed its projections regarding royalty revenues in light of recent updates to the Medicare Drug Price Negotiation Program. On November 5, 2026, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized rules that will influence how drug prices are negotiated, yet Halozyme anticipates little to no significant impact on its revenues through at least 2035.

Dr. Helen Torley, the company's President and CEO, stated, "We expect our royalty revenues to remain stable, largely based on our analysis of the recently issued final rule and its implications under the One Big Beautiful Bill Act (OBBBA)." This outlook is further reinforced by the continuation of orphan drug protections and the management of biosimilar entries that might otherwise complicate eligibility under the Program.

Halozyme's innovative approach is largely concentrated on its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of various treatments that significantly improve patient experiences. The technology employs the proprietary enzyme rHuPH20 to enhance the effectiveness and convenience of medication administration, reducing the treatment burden typically faced by patients. Over a million individuals have benefited from ENHANZE®, which has been successfully incorporated into ten commercial products across more than 100 global markets, in partnership with leading pharmaceutical firms such as Roche, Takeda, and Pfizer.

Halozyme’s business model highlights the significant potential of its hyperconcentration technologies, Hypercon™ and Aerocon™, which aim to set a new standard in drug delivery methods. These technologies reduce injection volumes while ensuring effective dosage administration, thereby enabling treatments to be performed in both clinical settings and home environments. The company has licensed this hyperconcentration technology to various notable biopharmaceutical partners, further illustrating its impact on the market.

Moreover, Halozyme is also active in developing advanced drug combination products that leverage auto-injector technologies to improve the overall patient experience, including its proprietary commercial products, Hylenex® and XYOSTED®. Strategic partnerships with major companies such as Teva Pharmaceuticals and Viatris Inc. complement Halozyme's product portfolio and developmental efforts.

The company's headquarters in San Diego is complemented by operations in Ewing, NJ, and Minnetonka, MN, where its key operational facility is located. For stakeholders and interested persons, additional information about Halozyme, its offerings, and strategic goals can be found on their official website and their LinkedIn page.

Future Expectations and Market Landscape

Halozyme's commitment to enhancing treatment methodologies through innovative solutions is expected to propel its operations and partnerships. The biopharmaceutical landscape is intricately linked to the regulatory environment; thus, Halozyme's outlook reflects a careful and informed analysis of the evolving drug pricing policies under Medicare.

Despite the uncertainties that often surround drug negotiations and pricing regulations, Halozyme’s position appears secure. The firm asserts that there should be